The effects of hemodilution on acute inflammatory responses in a bleomycin-induced lung injury model.
Acute normovolemic hemodilution (ANH) can be used in acute lung injury (ALI) patients who refuse blood transfusions. To investigate the effects of hemodilution on the acute inflammatory response in lung injury, the authors studied the effects of ANH in a rat model of bleomycin-induced lung injury. Bleomycin (10 mg/kg) was used to induce lung injury in 2 groups of rats. The treatment groups included a lung injury group with hemodilution (HI), a lung injury group without hemodilution (NHI), and a control group. Hemodilution was performed by removing blood and substituting the same amount of hydroxyethyl starch solution targeted to 7.0 g/dL via the right and left internal jugular veins. At day 3 after bleomycin instillation, systemic hemoglobin concentration was 9.5 +/- 1.1 g/dL. Tumor necrosis factor-alpha, interleukin-1beta, and interleukin-6 levels measured in the bronchoalveolar lavage fluid (BALF), blood, and lung tissue were not significantly different between the HI and NHI groups 3 days after lung injury. Microscopic findings showed fibrosis and inflammation in the HI and NHI groups 28 days after lung injury, but no significant differences were found between the 2 groups. Hemodilution after bleomycin administration did not further affect the acute inflammatory response or lung injury.
Cheong
Soon Ho
SH
Department of Anesthesia and Pain Medicine, Paik Hospital, Inje University, Busan, Republic of Korea. anesjsh@medimail.co.kr
Lee
Jeong Han
JH
Lee
Kun Moo
KM
Cho
Kwang Rae
KR
Yang
Young Il
YI
Seo
Ji Yeon
JY
Yoon
Sang Yeol
SY
Lee
Jeong Nyeo
JN
Choi
Min Young
MY
Lee
Sang Eun
SE
Kim
Young Hwan
YH
Lim
Se Hoon
SH
D055371:Acute Lung Injury / Q000139:chemically induced* / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D000740:Anemia / Q000097:blood / Q000150:complications / Q000628:therapy; D000818:Animals; D001761:Bleomycin / Q000633:toxicity*; D001804:Blood Transfusion, Autologous; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry / Q000166:cytology; D006438:Hemodilution / Q000009:adverse effects*; D006801:Humans; D007249:Inflammation / Q000378:metabolism / Q000473:pathology; D018836:Inflammation Mediators / Q000097:blood / Q000378:metabolism; D053583:Interleukin-1beta / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D018836:Inflammation Mediators; D053583:Interleukin-1beta; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D001761:Bleomycin